ADMA - ADMA Biologics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9100
-0.0450 (-1.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9550
Open3.9500
Bid0.0000 x 3200
Ask0.0000 x 4000
Day's Range3.8900 - 4.0200
52 Week Range2.0800 - 6.3130
Volume290,806
Avg. Volume746,467
Market Cap231.933M
Beta (3Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-1.2430
Earnings DateMar 7, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.19
Trade prices are not sourced from all markets
  • Should You Worry About ADMA Biologics, Inc.'s (NASDAQ:ADMA) CEO Salary Level?
    Simply Wall St.

    Should You Worry About ADMA Biologics, Inc.'s (NASDAQ:ADMA) CEO Salary Level?

    Adam Grossman became the CEO of ADMA Biologics, Inc. (NASDAQ:ADMA) in 2011. This report will, first, examine the CEO...

  • GlobeNewswire

    ADMA Biologics Announces Data Presented at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Announces Poster Presentation at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that Adam Grossman, President and Chief Executive Officer, and Brian Lenz, Executive Vice President and Chief Financial Officer, are scheduled to present a corporate overview at the Cantor Global Healthcare Conference, to be held October 2-4, 2019, at the InterContinental New York Barclay, in New York City.  ADMA is scheduled to present on Wednesday, October 2, 2019 at 10:40 AM ET.

  • What Kind Of Investor Owns Most Of ADMA Biologics, Inc. (NASDAQ:ADMA)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of ADMA Biologics, Inc. (NASDAQ:ADMA)?

    A look at the shareholders of ADMA Biologics, Inc. (NASDAQ:ADMA) can tell us which group is most powerful. Generally...

  • GlobeNewswire

    ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)
    Simply Wall St.

    Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)

    ADMA Biologics, Inc.'s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company...

  • GlobeNewswire

    ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.

  • Did ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Buy Up More Shares?
    Simply Wall St.

    Did ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • How Many ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • GuruFocus.com

    ADMA Biologics: Selloff Creates Buying Opportunity

    The fundamental growth story is intact

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 6, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • GuruFocus.com

    ADMA Biologics Is De-Risked and Ready to Rise

    After years of struggle, ADMA Biologics (ADMA) appears at last to be poised for bigger things. The Food and Drug Administration's recent approval of two of its intravenous immune globulin (IVIG) drug products, Asceniv and Bivigam, has put this stock back on the radar. Combined with a timely capital raise, ADMA's two new products should set it up for an impressive breakout in the second half of 2019.

  • GlobeNewswire

    ADMA Biologics to Present at Upcoming Investor Conferences

    Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech Conference RAMSEY, N.J. and BOCA RATON, Fla., May 29, 2019 -- ADMA Biologics, Inc. (NASDAQ:.

  • TheStreet.com

    These 3 Biotech Stocks Are Attracting Insider Buying

    Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.

  • GlobeNewswire

    ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public offering price of $4.00 per share, including 1,687,500 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering are $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

  • GuruFocus.com

    Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares

    President and CEO of Adma Biologics Inc (NASDAQ:ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share.

  • GlobeNewswire

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.

  • GlobeNewswire

    ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today that it has commenced a $45 million underwritten public offering of its common stock. The Company intends to grant the underwriter of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. Jefferies LLC is acting as sole book-running manager of the proposed offering.

  • GlobeNewswire

    FDA Approves Prior Approval Supplement for BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • Associated Press

    Adma Biologics: 1Q Earnings Snapshot

    The Ramsey, New Jersey-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring gains, came to 31 cents per share. The results topped Wall Street expectations. The average ...

  • GlobeNewswire

    ADMA Biologics Reports First Quarter 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection.  The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti-pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti-pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti-pneumococcal immune globulin.